Chongqing EVAHEART Medical Device Co., Ltd. announced that it has received $100 million in series A round of funding led by new investor Sinovac Biotech Co., Ltd. on March 9, 2023. The transaction also included participation from new investor China Taiping Insurance Holdings Company Limited, returning investor Vivo Capital, LLC.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.78 HKD | +1.86% | +3.91% | +30.65% |
May. 29 | China Taiping Insurance Units to Buy Five Aircraft | MT |
May. 28 | China Taiping Insurance Changes Auditor | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+30.65% | 4.04B | |
+11.66% | 99.82B | |
+4.52% | 98.28B | |
-14.25% | 83.27B | |
+19.42% | 75.31B | |
+19.05% | 34.06B | |
+17.28% | 30.49B | |
+19.09% | 30.31B | |
-0.47% | 17.1B | |
-12.95% | 14.5B |
- Stock Market
- Equities
- 966 Stock
- News China Taiping Insurance Holdings Company Limited
- Chongqing EVAHEART Medical Device Co., Ltd. announced that it has received $100 million in funding from Vivo Capital, LLC, Sinovac Biotech Co., Ltd., China Taiping Insurance Holdings Company Limited